Hanmi, emerging as strong competitor in domestic generic market

Published: 2008-06-09 06:57:00

Updated: 2008-06-09 06:57:00

Hanmi Pharm is expected to grab bigger pie in the nation’s generic market where many players are rushing to introduce first generic versions of off-patent drugs, according to a local analyst.

Kim Tae-hee, an analyst of Dongbu Securities, said that Hanmi has lead the first generic version launc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK